Kala Bio (Kala Bio) Cash-to-Debt : 1.40 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Kala Bio Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Kala Bio's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.40.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Kala Bio could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Kala Bio's Cash-to-Debt or its related term are showing as below:

KALA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.59 Med: 1.52 Max: 6.01
Current: 1.4

During the past 9 years, Kala Bio's highest Cash to Debt Ratio was 6.01. The lowest was 0.59. And the median was 1.52.

KALA's Cash-to-Debt is ranked worse than
72.19% of 1539 companies
in the Biotechnology industry
Industry Median: 6.46 vs KALA: 1.40

Kala Bio Cash-to-Debt Historical Data

The historical data trend for Kala Bio's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Kala Bio Cash-to-Debt Chart

Kala Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.84

1.52

1.15

1.64

1.40

Kala Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															1.64	1.91	1.76	1.55	1.40

Competitive Comparison of Kala Bio's Cash-to-Debt

For the Biotechnology subindustry, Kala Bio's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kala Bio's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kala Bio's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Kala Bio's Cash-to-Debt falls into.

Kala Bio Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Kala Bio's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	50.895	/	(0.334	+	35.989)
	=	1.40

Kala Bio's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	50.895	/	(0.334	+	35.989)
	=	1.40

Kala Bio (NAS:KALA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Kala Bio Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Kala Bio's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kala Bio (Kala Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (NAS:KALA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

27F0:Germany

Address

1167 Massachusetts Avenue, Arlington, MA, USA, 02476

Website

https://www.kalarx.com

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Executives

Todd Bazemore	officer: Chief Operating Officer	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Romulus K Brazzell	officer: Chief Medical Officer	C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Eric Trachtenberg	officer: See Remarks	1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Darius Kharabi	officer: CHIEF BUSINESS OFFICER	C/O KALA PHARMACEUTICALS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Mark T Iwicki	director, officer: Chief Executive Officer	84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Mary Reumuth	officer: Chief Financial Officer	100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Marjan Farid	director	C/O KALA PHARMACEUTICALS, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON MA 02476
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Mark S. Blumenkranz	director	C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Hongming Chen	officer: Chief Scientific Officer	100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
C. Daniel Myers	director	6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Gregory Grunberg	director	100 BEAVER STREET, WALTHAM MA 02453
Rajeev M. Shah	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116